Differential effects on lung cancer cell proliferation by agonists of glucocorticoid and PPARα receptors

Molecular Carcinogenesis

Volumn 53, Issue 9, 2014, Pages 753-763

  Liang, Huiyun ^a,b   Kowalczyk, Piotr ^a   Junco, Jacob J ^a   Klug De Santiago, Heather L ^b   Malik, Gunjan ^a   Wei, Sung Jen ^a,b   Slaga, Thomas J ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b UNIVERSITY OF TEXAS PAN AMERICAN   (United States)

Author keywords

Budesonide; Fenofibrate; Glucocorticoid receptor (GR); Lung cancer; Peroxisome proliferator activated receptor (PPAR )

Indexed keywords

BUDESONIDE; CYCLINE; FENOFIBRATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PROTEIN P53; ANTIINFLAMMATORY AGENT; ANTILIPEMIC AGENT; GLUCOCORTICOID RECEPTOR; MESSENGER RNA; TP53 PROTEIN, HUMAN;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL; CELL CYCLE; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; G1 PHASE CELL CYCLE CHECKPOINT; LUNG CANCER; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; WILD TYPE; ADENOCARCINOMA; AGONISTS; DRUG EFFECTS; FLOW CYTOMETRY; GENETICS; HUMAN; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ADENOCARCINOMA; ANTI-INFLAMMATORY AGENTS; BLOTTING, WESTERN; BUDESONIDE; CELL CYCLE; CELL PROLIFERATION; FENOFIBRATE; FLOW CYTOMETRY; HUMANS; HYPOLIPIDEMIC AGENTS; LUNG NEOPLASMS; NF-KAPPA B; PPAR ALPHA; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, GLUCOCORTICOID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84906097404     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22029     Document Type: Article

References (71)

1. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454:436-444.
2. Mantovani A, Pierotti MA. Cancer and inflammation: A complex relationship. Cancer Lett 2008; 267:180-181.
3. Schetter AJ, Heegaard NH, Harris CC. Inflammation and cancer: Interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis 2010; 31:37-49.
4. Vayssiere BM, Dupont S, Choquart A, et al. Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo. Mol Endocrinol 1997; 11:1245-1255.
5. McColl A, Michlewska S, Dransfield I, Rossi AG. Effects of glucocorticoids on apoptosis and clearance of apoptotic cells. Sci World J 2007; 7:1165-1181.
6. Langeveld CH, van Waas MP, Stoof JC, et al. Implication of glucocorticoid receptors in the stimulation of human glioma cell proliferation by dexamethasone. J Neurosci Res 1992; 31:524-531.
7. Cai J, Zheng T, Lotz M, Zhang Y, Masood R, Gill P. Glucocorticoids induce Kaposi's sarcoma cell proliferation through the regulation of transforming growth factor-beta. Blood 1997; 89:1491-1500.
8. Greenberg AK, Hu J, Basu S, et al. Glucocorticoids inhibit lung cancer cell growth through both the extracellular signal-related kinase pathway and cell cycle regulators. Am J Respir Cell Mol Biol 2002; 27:320-328.
9. Robinson-Rechavi M, Escriva Garcia H, Laudet V. The nuclear receptor superfamily. J Cell Sci 2003; 116:585-586.
10. Huang P, Chandra V, Rastinejad F. Structural overview of the nuclear receptor superfamily: Insights into physiology and therapeutics. Annu Rev Physiol 2010; 72:247-272.
11. Moore JT, Collins JL, Pearce KH. The nuclear receptor superfamily and drug discovery. ChemMedChem 2006; 1:504-523.
12. Michalik L, Auwerx J, Berger JP, et al. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev 2006; 58:726-741.
13. Schupp M, Lazar MA. Endogenous ligands for nuclear receptors: Digging deeper. J Biol Chem 2010; 285:40409-40415.
14. Auboeuf D, Rieusset J, Fajas L, et al. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: No alteration in adipose tissue of obese and NIDDM patients. Diabetes 1997; 46:1319-1327.
15. Mandard S, Muller M, Kersten S. Peroxisome proliferator-activated receptor alpha target genes. Cell Mol Life Sci 2004; 61:393-416.
16. Ahmed W, Ziouzenkova O, Brown J, et al. PPARs and their metabolic modulation: New mechanisms for transcriptional regulation? J Intern Med 2007; 262:184-198.
17. Finck BN, Kelly DP. Peroxisome proliferator-activated receptor alpha (PPARalpha) signaling in the gene regulatory control of energy metabolism in the normal and diseased heart. J Mol Cell Cardiol 2002; 34:1249-1257.
18. Cornu-Chagnon MC, Dupont H, Edgar A. Fenofibrate: Metabolism and species differences for peroxisome proliferation in cultured hepatocytes. Fundam Appl Toxicol 1995; 26:63-74.
19. Delerive P, De Bosscher K, Besnard S, et al. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem 1999; 274:32048-32054.
20. Bougarne N, Paumelle R, Caron S, et al. PPARalpha blocks glucocorticoid receptor alpha-mediated transactivation but cooperates with the activated glucocorticoid receptor alpha for transrepression on NF-kappaB. Proc Natl Acad Sci USA 2009; 106:7397-7402.
21. Yamasaki D, Kawabe N, Nakamura H, et al. Fenofibrate suppresses growth of the human hepatocellular carcinoma cell via PPARalpha-independent mechanisms. Eur J Cell Biol 2011; 90:657-664.
22. Zak Z, Gelebart P, Lai R. Fenofibrate induces effective apoptosis in mantle cell lymphoma by inhibiting the TNFalpha/NF-kappaB signaling axis. Leukemia 2010; 24:1476-1486.
23. Jiao HL, Zhao BL. Cytotoxic effect of peroxisome proliferator fenofibrate on human HepG2 hepatoma cell line and relevant mechanisms. Toxicol Appl Pharmacol 2002; 185:172-179.
24. Yao R, Wang Y, Lemon WJ, Lubet RA, You M. Budesonide exerts its chemopreventive efficacy during mouse lung tumorigenesis by modulating gene expressions. Oncogene 2004; 23:7746-7752.
25. Pereira MA, Li Y, Gunning WT, et al. Prevention of mouse lung tumors by budesonide and its modulation of biomarkers. Carcinogenesis 2002; 23:1185-1192.
26. Wang Y, Zhang Z, Kastens E, Lubet RA, You M. Mice with alterations in both p53 and Ink4a/Arf display a striking increase in lung tumor multiplicity and progression: Differential chemopreventive effect of budesonide in wild-type and mutant A/J mice. Cancer Res 2003; 63:4389-4395.
27. Balansky R, Ganchev G, Iltcheva M, Steele VE, De Flora S. Prevention of cigarette smoke-induced lung tumors in mice by budesonide, phenethyl isothiocyanate, and N-acetylcysteine. Int J Cancer 2010; 126:1047-1054.
28. Pirotte B, Levivier M, Goldman S, Brucher JM, Brotchi J, Hildebrand J. Glucocorticoid-induced long-term remission in primary cerebral lymphoma: Case report and review of the literature. J Neurooncol 1997; 32:63-69.
29. Sionov RV, Spokoini R, Kfir-Erenfeld S, Cohen O, Yefenof E. Mechanisms regulating the susceptibility of hematopoietic malignancies to glucocorticoid-induced apoptosis. Adv Cancer Res 2008; 101:127-248.
30. Planey SL, Litwack G. Glucocorticoid-induced apoptosis in lymphocytes. Biochem Biophys Res Commun 2000; 279:307-312.
31. Gross KL, Lu NZ, Cidlowski JA. Molecular mechanisms regulating glucocorticoid sensitivity and resistance. Mol Cell Endocrinol 2009; 300:7-16.
32. Tanaka T, Kohno H, Yoshitani S, et al. Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Res 2001; 61:2424-2428.
33. Yokoyama Y, Xin B, Shigeto T, et al. Clofibric acid, a peroxisome proliferator-activated receptor alpha ligand, inhibits growth of human ovarian cancer. Mol Cancer Ther 2007; 6:1379-1386.
34. Pozzi A, Ibanez MR, Gatica AE, et al. Peroxisomal proliferator-activated receptor-alpha-dependent inhibition of endothelial cell proliferation and tumorigenesis. J Biol Chem 2007; 282:17685-17695.
35. Kaipainen A, Kieran MW, Huang S, et al. PPARalpha deficiency in inflammatory cells suppresses tumor growth. PLoS ONE 2007; 2:e260.
36. Panigrahy D, Kaipainen A, Huang S, et al. PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc Natl Acad Sci USA 2008; 105:985-990.
37. De Bosscher K, Haegeman G, Minireview: Latest perspectives on antiinflammatory actions of glucocorticoids. Mol Endocrinol 2009; 23:281-291.
38. Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002; 96:23-43.
39. Barnes PJ, Adcock IM. Glucocorticoid resistance in inflammatory diseases. Lancet 2009; 373:1905-1917.
40. Schmidt S, Rainer J, Ploner C, Presul E, Riml S, Kofler R. Glucocorticoid-induced apoptosis and glucocorticoid resistance: Molecular mechanisms and clinical relevance. Cell Death Differ 2004; 11:S45-S55.
41. Alberg AJ, Brock MV, Samet JM. Epidemiology of lung cancer: Looking to the future. J Clin Oncol 2005; 23:3175-3185.
42. Takahashi T. Lung cancer: An ever increasing store of in-depth basic knowledge and the beginning of its clinical application. Oncogene 2002; 21:6868-6869.
43. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008; 359:1367-1380.
44. Zhou JR, Yu L, Zerbini LF, Libermann TA, Blackburn GL. Progression to androgen-independent LNCaP human prostate tumors: Cellular and molecular alterations. Int J Cancer 2004; 110:800-806.
45. Larsson LG. Oncogene- and tumor suppressor gene-mediated suppression of cellular senescence. Semin Cancer Biol 2011; 21:367-376.
46. Kawasaki T, Tomita Y, Bilim V, Takeda M, Takahashi K, Kumanishi T. Abrogation of apoptosis induced by DNA-damaging agents in human bladder-cancer cell lines with p21/WAF1/CIP1 and/or p53 gene alterations. Int J Cancer 1996; 68:501-505.
47. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59:225-249.
48. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108.
49. Esposito L, Conti D, Ailavajhala R, Khalil N, Giordano A. Lung cancer: Are we up to the challenge? Curr Genomics 2010; 11:513-518.
50. Belani CP. Chemotherapy regimens in advanced non-small-cell lung cancer: Recent randomized trials. Clin Lung Cancer 2002; 3:S5-S9.
51. Thatcher N, Ranson M, Lee SM, Niven R, Anderson H. Chemotherapy in non-small cell lung cancer. Ann Oncol 1995; 6:83-94; discussion 94-85.
52. Buttgereit F, Burmester GR, Lipworth BJ. Optimised glucocorticoid therapy: The sharpening of an old spear. Lancet 2005; 365:801-803.
53. Zhou J, Cidlowski JA. The human glucocorticoid receptor: One gene, multiple proteins and diverse responses. Steroids 2005; 70:407-417.
54. Coleman RE. Glucocorticoids in cancer therapy. Biotherapy 1992; 4:37-44.
55. Herr I, Pfitzenmaier J. Glucocorticoid use in prostate cancer and other solid tumours: Implications for effectiveness of cytotoxic treatment and metastases. Lancet Oncol 2006; 7:425-430.
56. Yemelyanov A, Czwornog J, Chebotaev D, et al. Tumor suppressor activity of glucocorticoid receptor in the prostate. Oncogene 2007; 26:1885-1896.
57. Keith BD. Systematic review of the clinical effect of glucocorticoids on nonhematologic malignancy. BMC Cancer 2008; 8:84.
58. Wattenberg LW, Wiedmann TS, Estensen RD, Zimmerman CL, Steele VE, Kelloff GJ. Chemoprevention of pulmonary carcinogenesis by aerosolized budesonide in female A/J mice. Cancer Res 1997; 57:5489-5492.
59. Wattenberg LW, Wiedmann TS, Estensen RD, et al. Chemoprevention of pulmonary carcinogenesis by brief exposures to aerosolized budesonide or beclomethasone dipropionate and by the combination of aerosolized budesonide and dietary myo-inositol. Carcinogenesis 2000; 21:179-182.
60. Balansky R, Ganchev G, Iltcheva M, Steele VE, De Flora S. Prenatal N-acetylcysteine prevents cigarette smoke-induced lung cancer in neonatal mice. Carcinogenesis 2009; 30:1398-1401.
61. Lazzeroni M, Guerrieri-Gonzaga A, Serrano D, et al. Budesonide versus placebo in high-risk population with screen-detected lung nodules: Rationale, design and methodology. Contemp Clin Trials 2010; 31:612-619.
62. Veronesi G, Szabo E, Decensi A, et al. Randomized phase II trial of inhaled budesonide versus placebo in high-risk individuals with CT screen-detected lung nodules. Cancer Prev Res (Phila) 2011; 4:34-42.
63. Reddy JK, Azarnoff DL, Hignite CE. Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens. Nature 1980; 283:397-398.
64. Peters JM, Cattley RC, Gonzalez FJ. Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-146, 43. Carcinogenesis 1997; 18:2029-2033.
65. Grabacka M, Placha W, Plonka PM, et al. Inhibition of melanoma metastases by fenofibrate. Arch Dermatol Res 2004; 296:54-58.
66. Grabacka M, Plonka PM, Urbanska K, Reiss K. Peroxisome proliferator-activated receptor alpha activation decreases metastatic potential of melanoma cells in vitro via down-regulation of Akt. Clin Cancer Res 2006; 12:3028-3036.
67. Zuo Z, Urban G, Scammell JG, et al. Ser/Thr protein phosphatase type 5 (PP5) is a negative regulator of glucocorticoid receptor-mediated growth arrest. Biochemistry 1999; 38:8849-8857.
68. Sengupta S, Vonesch JL, Waltzinger C, Zheng H, Wasylyk B. Negative cross-talk between p53 and the glucocorticoid receptor and its role in neuroblastoma cells. EMBO J 2000; 19:6051-6064.
69. Roth M, Johnson PR, Borger P, et al. Dysfunctional interaction of C/EBPalpha and the glucocorticoid receptor in asthmatic bronchial smooth-muscle cells. N Engl J Med 2004; 351:560-574.
70. Cha HH, Cram EJ, Wang EC, Huang AJ, Kasler HG, Firestone GL. Glucocorticoids stimulate p21 gene expression by targeting multiple transcriptional elements within a steroid responsive region of the p21waf1/cip1 promoter in rat hepatoma cells. J Biol Chem 1998; 273:1998-2007.
71. Cram EJ, Ramos RA, Wang EC, Cha HH, Nishio Y, Firestone GL. Role of the CCAAT/enhancer binding protein-alpha transcription factor in the glucocorticoid stimulation of p21waf1/cip1 gene promoter activity in growth-arrested rat hepatoma cells. J Biol Chem 1998; 273:2008-2014.